Circulating lncRNA XLOC_009167 serves as a diagnostic biomarker to predict lung cancer

Jiang, Nan; Meng, Xiaoxiao; Mi, Hongchao; Chi, Yidi; Li, Shenghui; Jin, Zeyu; Tian, Hui; He, Jiamin; Shen, Weiyu; Tian, Haihua; Pan, Jinchang; Fang, Shuai; Jin, Xiaofeng; Zhou, Chengwei; Gong, Zhaohui

doi:10.1016/j.cca.2018.07.026

Cited by 96 publications

(69 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The consistent result further enhanced the reliability in the plasma examination. Recent studies have demonstrated that lncRNAs, including pseudogene, were present in the blood of cancer patients and showed great potential as powerful and non-invasive tumor markers [25][26][27]. Our results indicate KRT17P3 maybe a potential non-invasive tumor markers for discriminating against cisplatin resistant patients and sensitive patients.…”

Section: Discussionsupporting

confidence: 51%

Pseudogene KRT17P3 Drives Cisplatin Resistance of Human NSCLC Cells by Modulating miR-497-5p/mTOR

Hou

Zhou

Xia

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Chemoresistance is a major obstacle in non-small-cell lung cancer (NSCLC) treatment. The pseudogene KRT17P3 has been shown to be up-regulated in lung cancer tissues from patients with cisplatin resistance. However, its molecular mechanism in promoting chemoresistance has not been elucidated.Methods: Real-time PCR was performed to evaluate KRT17P3 levels in plasma samples collected from 30 cisplatin-resistance patients and 32 cisplatin-sensitive patients. KRT17P3 was overexpressed or knocked down in A549 and SK-MES-1 NSCLC cells to evaluate the effects of KRT17P3 on the in vitro and in vivo resistance of NSCLC to cisplatin. Cell Counting Kit 8, Annexin V/propidium iodide staining, and PARP-1 cleavage assays were performed to evaluate cell viability and apoptosis. Dual luciferase reporter, RNA immunoprecipitation, Western blot assays, and rescue experiments were used to evaluate the functional interaction of KRT17P3, miR-497-5p and mTOR.Results: Our results demonstrate that KRT17P3 overexpression in cultured NSCLC cells increases cell viability and decreases apoptosis upon cisplatin treatment, while KRT17P3 knockdown has the opposite effect. KRT17P3 overexpression promotes NSCLC tumor growth upon in cisplatin-treated xenografted mice. Mechanistically, KRT17P3 acts as a molecular sponge for miR-497-5p and relieves the binding of miR-497-5p to its target gene mTOR. Rescue experiments validated the functional interaction among KRT17P3, miR497-5p, and mTOR. Moreover, the plasma level of KRT17P3 is up-regulated in cisplatin-resistance patients.Conclusions: Our findings indicate that KRT17P3/miR497-5p/mTOR regulates the chemosensitivity of NSCLC, suggesting a potential therapeutic target for cisplatin-resistant NSCLC patients. KRT17P3 may be a potential peripheral blood marker of NSCLC patients resistant to cisplatin.

show abstract

Section: Discussionsupporting

confidence: 51%

Pseudogene KRT17P3 Drives Cisplatin Resistance of Human NSCLC Cells by Modulating miR-497-5p/mTOR

Hou

Zhou

Xia

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…For example, in human cancer, lncRNAs have been showed to be useful potential diagnostic markers: lncRNA XLOC_009167 was screened as a candidate biomarker for lung cancer by Jiang et al, (2018). Their findings showed that lncRNA XLOC_009167 was hugely overexpressed in human blood and gave a better idea of disease progression compared to other current available diagnostic tools suggesting that lncRNAs could be utilized as an essential tool for detection as well as monitoring lung cancer (Jiang et al, 2018). In hepatocellular carcinoma (HCC), another oncogenic lncRNA, uc007biz.1 (LRB1) has been reported to act as a marker for the determining disease pathogenicity (Wang et al, 2018d).…”

Section: Potential Applications Of Lncrnas In Tcmentioning

confidence: 99%

LncRNAs as Potential Therapeutic Targets in Thyroid Cancer

Javed

Shah

Rajabi

et al. 2020

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Thyroid cancer (TC) is the most common cancer of endocrine system. TC can be subdivided into 4 different entities, papillary, follicular, medullary and anaplastic thyroid cancer. Among them, anaplastic thyroid cancer has the poorest prognosis. Exploring new therapeutic approach may entail favorable prediction as well as increasing overall survival rate of patients. Long non-coding RNAs (lncRNAs), have vast implications in different cancer types. Although they are not transcribed into proteins, they can act as a harness in regulating a plethora of biological functions. They have been implicated in a decisive role in gene expression via modulation of both coding and non-coding RNAs. This article discuss the multi-facet role of lncRNA in thyroid cancer biology.

show abstract

“…Some lncRNAs that aberrantly expressed in disease progression have potentials to serve as biomarkers and/or therapeutic targets [24]. For example, the upregulated circulating expression of lncRNA XLOC_009167 in lung cancer patients has been demonstrated to be a candidate diagnostic biomarker [25]. The increased lncRNA TUG1 in atherosclerosis could promote vascular smooth muscle cell proliferation, and contributes atherosclerosis development by regulating the miR-21/PTEN axis [26].…”

Section: Discussionmentioning

confidence: 99%

Elevated Circulating LINC-P21 Serves as a Diagnostic Biomarker of Type 2 Diabetes Mellitus and Regulates Pancreatic β-cell Function by Sponging miR-766-3p to Upregulate NR3C2

Cao

Yao

Lang

et al. 2020

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

Objective The purpose of this study was to evaluate the clinical value and biological function of long non-coding RNA (lncRNA) LINC-P21 in type 2 diabetes mellitus (T2DM), and explore the underlying mechanisms. Methods The expression of LINC-P21 was estimated using quantitative real-time PCR. The functional role of LINC-P21 was explored by gain- and loss-of-function experiments. INS-1 cell proliferation was analyzed using a cell counting kit-8 (CCK-8)assay, and the glucose-stimulated insulin secretion was measured using an ELISA kit. The miRNAs that might be sponged by LINC-P21 were analyzed, and the subsequent target genes were predicted and assessed in INS-1 cells. Results Serum expression of LINC-P21 was elevated in T2DM patients, which was correlated with fasting blood glucose levels and disease diagnosis. The glucose-stimulated insulin secretion and the proliferation of INS-1 cells were enhanced by LINC-P21 knockdown, but the overexpression of LINC-P21 led to opposite effects. miR-766-3p could be directly inhibited by LINC-P21 in INS-1 cells and reverse the effects of LINC-P21 on β-cell function. Additionally, NR3C2 was determined as a target of miR-766-3p, which could be positively regulated by LINC-P21 and had same effects with LINC-P21 on INS-1 cell proliferation and insulin secretion. Conclusion All the data demonstrated that serum elevated LINC-P21 and decreased miR-766-3p serve as candidate diagnostic biomarkers in T2DM patients. LINC-P21 acts as a potential regulator in insulin secretion and proliferation of pancreatic β-cells through targeting miR-766-3p to upregulate NR3C2.

show abstract

Circulating lncRNA XLOC_009167 serves as a diagnostic biomarker to predict lung cancer

Cited by 96 publications

References 36 publications

Pseudogene KRT17P3 Drives Cisplatin Resistance of Human NSCLC Cells by Modulating miR-497-5p/mTOR

Pseudogene KRT17P3 Drives Cisplatin Resistance of Human NSCLC Cells by Modulating miR-497-5p/mTOR

LncRNAs as Potential Therapeutic Targets in Thyroid Cancer

Elevated Circulating LINC-P21 Serves as a Diagnostic Biomarker of Type 2 Diabetes Mellitus and Regulates Pancreatic β-cell Function by Sponging miR-766-3p to Upregulate NR3C2

Contact Info

Product

Resources

About